Cited by 888Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Diabetic dyslipidaemia: from basic research to clinical practice*

Open access

Taskinen, M.-R.·2003·Diabetologia

DOI 10.1007/s00125-003-1111-y

Open this paper in CoChat — free account Open PDF

Abstract

The recognition that the increase of plasma triglyceride rich lipoproteins (TRLs) is associated with multiple alterations of other lipoproteins species that are potentially atherogenic has expanded the picture of diabetic dyslipidaemia. The discovery of heterogeneity within major lipoprotein classes VLDL, LDL and HDL opened new avenues to reveal the specific pertubations of diabetic dyslipidaemia. The increase of large VLDL 1 particles in Type 2 diabetes initiates a sequence of events that generates atherogenic remnants, small dense LDL and small dense HDL particles. Together these components comprise the atherogenic lipid triad. Notably the malignant nature of diabetic dyslipidaemia is not completely shown by the lipid measures used in clinical practice. The key question is what are the mechanisms behind the increase of VLDL 1 particles in diabetic dyslipidaemia? Despite the advances of recent years, our understanding of VLDL assembly and secretion is still surprisingly incomplete. To date it is still unclear how the liver is able to regulate the amount of triglycerides incorporated into VLDL particles to produce either VLDL 1 or VLDL 2 particles. The current evidence suggests that the machinery driving VLDL assembly in the liver includes (i) low insulin signalling via PI-3 kinase pathway that enhances lipid accumulation into "nascent " VLDL particles (ii) up-regulation of SREBP-1C that stimulates de novo lipogenesis and (iii) excess availability of "polar molecules" in hepatocytes that stabilizes apo B 100. Recent data suggest that all these steps could be fundamentally altered in Type 2 diabetes explaining the overproduction of VLDL apo B as well as the ability of insulin to suppress VLDL 1 apo B production in Type 2 diabetes. Recent discoveries have established the transcription factors including PPARs, SREBP-1 and LXRs as the key regulators of lipid assembly in the liver. These observations suggest these factors as a new target to tailor more efficient drugs to treat diabetic dyslipidaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-003-1111-y

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Self-citation
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014

Show all 183 references

Sorted by citations

Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
“hyperinsulinemia, abnormalities in adipokines and adipocytokines have been implicated [190].”
Background
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
Tangvarasittichai, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.456 · Cited by 1,284
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,053
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Self-citation
HDL and Reverse Cholesterol Transport
Ouimet, M. I., Barrett, T. J., & Fisher, E. A. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 816
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citation
Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer
Matsuda, M., & Shimomura, I. (2013) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2013.05.004 · Cited by 651
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 646
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 536
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Self-citation
Diabetes Dyslipidemia
Schofield, J. D., Liu, Y., Rao‐Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 447
Purified Anthocyanin Supplementation Reduces Dyslipidemia, Enhances Antioxidant Capacity, and Prevents Insulin Resistance in Diabetic Patients1–3
Li, D., Zhang, Y., Liu, Y., Sun, R., & Xia, M. (2015) · Journal of Nutrition · doi:10.3945/jn.114.205674 · Cited by 392
Diabetes and lipid metabolism
Athyros, V. G., Doumas, M. N., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0014-8 · Cited by 384
American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity
Boström, P., Andersson, L. K., Rutberg, M., Perman, J., Lidberg, U., Johansson, B. R., Fernández-Rodrı́guez, J., Ericson, J., Nilsson, T., Borén, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1648 · Cited by 359
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Self-citation
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Self-citation
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
Olofsson, S. ‐., & Borén, J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01556.x · Cited by 342
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Lipid and lipoprotein dysregulation in insulin resistant states
Avramoglu, R. K., Basciano, H., & Adeli, K. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.026 · Cited by 326
Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins
Borggreve, S. E., Vries, R. D., & Dullaart, R. P. F. (2003) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2003.01263.x · Cited by 277
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia
Adiels, M., Borén, J., CASLAKE, M. J., Stewart, P., Soro, A., Westerbacka, J., Wennberg, B., Olofsson, S., Packard, C. J., & Taskinen, M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000172689.53992.25 · Cited by 275
Self-citation
Lipid droplets as dynamic organelles connecting storage and efflux of lipids
Olofsson, S., Boström, P., Andersson, L. K., Rutberg, M., Perman, J., & Borén, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.08.001 · Cited by 273
Obesity and dyslipidemia
Franssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.003 · Cited by 270
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Intracellular Trafficking and Secretion of VLDL
Tiwari, S., & Siddiqi, S. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241471 · Cited by 257
Mechanisms of Disease: adipocytokines and visceral adipose tissue—emerging role in nonalcoholic fatty liver disease
Schäffler, A., Schölmerich, J., & Büchler, C. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0186 · Cited by 240
Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?
Cleland, S. J., Fisher, B. M., Colhoun, H. M., Sattar, N. A., & Petrie, J. R. (2013) · Diabetologia · doi:10.1007/s00125-013-2904-2 · Cited by 251
PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic Adaptation
Contreras, A. V., Torres, N., & Tovar, A. R. (2013) · Advances in Nutrition · doi:10.3945/an.113.003798 · Cited by 244
Ectopic lipid storage and insulin resistance: a harmful relationship
Borén, J., Taskinen, M., Olofsson, S. ‐., & Levin, M. C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12071 · Cited by 240
Self-citation
Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia
Nob�court, E., Jacqueminet, S., Hansel, B., Chantepie, S., Grimaldi, A., Chapman, M. J., & Kontush, A. (2005) · Diabetologia · doi:10.1007/s00125-004-1655-5 · Cited by 222
The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk
Femlak, M., Gluba-Brzózka, A., Ciałkowska-Rysz, A. D., & Rysz, J. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0594-3 · Cited by 226
Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36
Hsieh, J., Longuet, C., Maida, A., Bahrami, J., Xu, E., Baker, C. L., Brubaker, P. L., Drucker, D. J., & Adeli, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.051 · Cited by 214
Cardiovascular metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease
Rana, J. S., Nieuwdorp, M., Jukema, J. W., & Kastelein, J. J. P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00594.x · Cited by 212
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes
Krentz, A. J. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2003.0310.x · Cited by 205
Nobiletin Attenuates VLDL Overproduction, Dyslipidemia, and Atherosclerosis in Mice With Diet-Induced Insulin Resistance
Mulvihill, E. E., Assini, J. M., Lee, J. K., Allister, E. M., Sutherland, B. G., Koppes, J. B., Sawyez, C. G., Edwards, J. Y., Telford, D. E., Charbonneau, A., et al. (2011) · Diabetes · doi:10.2337/db10-0589 · Cited by 202
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 205
Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance
Adiels, M., Westerbacka, J., Soro‐Paavonen, A., Häkkinen, A. ‐., Vehkavaara, S., CASLAKE, M. J., Packard, C. J., Olofsson, S.-O., Yki‐Järvinen, H., Taskinen, M., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 197
Self-citation
Influence of Hepatic Steatosis (Fatty Liver) on Severity and Composition of Dyslipidemia in Type 2 Diabetes
Toledo, F. G. S., Sniderman, A. D., & Kelley, D. E. (2006) · Diabetes Care · doi:10.2337/dc06-0455 · Cited by 196
Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study
Özder, A. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-183 · Cited by 195
Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes
Sharma, A. K., Bharti, S., Ojha, S. K., Bhatia, J., Kumar, N., Ray, R., Kumari, S., & Arya, D. S. (2011) · British Journal Of Nutrition · doi:10.1017/s000711451100225x · Cited by 186
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
Marcovina, S. M., & Packard, C. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01648.x · Cited by 180
PLD1 and ERK2 regulate cytosolic lipid droplet formation
Andersson, L. K., Boström, P., Ericson, J., Rutberg, M., Magnusson, B., Marchesan, D., Ruiz, M., Asp, L., Huang, P. C., Frohman, M. A., et al. (2006) · Journal of Cell Science · doi:10.1242/jcs.02941 · Cited by 180
High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease
Rohrer, L., Hersberger, M., & von Eckardstein, A. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00006 · Cited by 175
Beyond Low-Density Lipoprotein
Nesto, R. W. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00005 · Cited by 176
Diabetic dyslipidaemia
Adiels, M., Olofsson, S., Taskinen, M., & Borén, J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226115.97436.c0 · Cited by 179
Self-citation
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
Bril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo-Sánchez, P., Biernacki, D., Maximos, M., Lomonaco, R., Orsak, B., Suman, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3111 · Cited by 168
Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin
Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., Babaya, N., Itoi‐Babaya, M., Yamaji, K., Hiromine, Y., et al. (2006) · Diabetes · doi:10.2337/db06-0353 · Cited by 166
Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study
Kazé, A. D., Santhanam, P., Musani, S. K., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016947 · Cited by 177
Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Obesity
Brehm, A., Pfeiler, G., Pacini, G., Vierhapper, H., & Roden, M. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.037556 · Cited by 169
Insulin signaling to hepatic lipid metabolism in health and disease
Leavens, K. F., & Birnbaum, M. J. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.562481 · Cited by 169
Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study
Langsted, A., & Nordestgaard, B. G. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157164 · Cited by 160
Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?
Drexel, H., Aczél, S., Marte, T., Benzer, W., Langer, P. H., Moll, W., & Saely, C. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.101 · Cited by 161
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
Hu, X., Liu, Q., Guo, X., Wang, W., Yu, B., Liang, B., Zhou, Y., Dong, H., & Lin, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01554-0 · Cited by 150
Serum triglycerides and risk of cardiovascular disease
Boullart, A. C. I., Graaf, J. D., & Stalenhoef, A. F. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.002 · Cited by 159
Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells
Abderrahmani, A., Niederhäuser, G., Favre, D., Abdelli, S., Ferdaoussi, M., Yang, J. Y., Regazzi, R., Widmann, C., & Waeber, G. (2007) · Diabetologia · doi:10.1007/s00125-007-0642-z · Cited by 147
Utility of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Evaluating Incident Diabetes Risk
Sheng, G., Liu, D., Kuang, M., Zhong, Y., Zhang, S., & Zou, Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s355980 · Cited by 148
Fatty liver, insulin resistance, and dyslipidemia
Adiels, M., Taskinen, M., & Borén, J. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0011-4 · Cited by 147
Self-citation
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer
Bao, J., Zhu, L., Zhu, Q., Su, J., Liu, M., & Huang, W. (2016) · Oncology Letters · doi:10.3892/ol.2016.4988 · Cited by 143
Triglycerides and Cardiovascular Risk
Harchaoui, K. E., Visser, M., Kastelein, J. J. P., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970315 · Cited by 140
SREBP-1 Has a Prognostic Role and Contributes to Invasion and Metastasis in Human Hepatocellular Carcinoma
Li, C., Yang, W., Zhang, J., Zheng, X. M., Yao, Y., Tu, K., & Liu, Q. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057124 · Cited by 138
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132
Self-citation
Renal Lipid Metabolism and Lipotoxicity in Diabetes
Thongnak, L., Pongchaidecha, A., & Lungkaphin, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.11.004 · Cited by 133
Intestinal Insulin Resistance and Aberrant Production of Apolipoprotein B48 Lipoproteins in an Animal Model of Insulin Resistance and Metabolic Dyslipidemia
Federico, L. M., Naples, M., Taylor, D., & Adeli, K. (2006) · Diabetes · doi:10.2337/db04-1084 · Cited by 132
Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease
Packard, C. J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236367.42755.c1 · Cited by 127
Mobile health (mHealth) based medication adherence measurement – a pilot trial using electronic blisters in diabetes patients
Brath, H., Morak, J., Kästenbauer, T., Modre‐Osprian, R., Strohner‐Kästenbauer, H., Schwarz, M., Kort, W., & Schreier, G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12184 · Cited by 121
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 131
Cardiovascular risk in women with diabetes
Rivellese, A. A., Riccardi, G., & Vaccaro, O. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.01.008 · Cited by 125
New insight into the pathophysiology of lipid abnormalities in type 2 diabetes
Vergès, B. L. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70213-6 · Cited by 134
Glycation of paraoxonase‐1 inhibits its activity and impairs the ability of high‐density lipoprotein to metabolize membrane lipid hydroperoxides
Mastorikou, M., Mackness, B., Liu, Y., & Mackness, M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02546.x · Cited by 122
Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients With Type 2 Diabetes and Effect of Metformin
Rabbani, N., Chittari, M. V., Bodmer, C. W., Zehnder, D., Ceriello, A., & Thornalley, P. J. (2010) · Diabetes · doi:10.2337/db09-1455 · Cited by 125
Herbal or Natural Medicines as Modulators of Peroxisome Proliferator‐Activated Receptors and Related Nuclear Receptors for Therapy of Metabolic Syndrome
Huang, T. H.-W., Kota, B. P., Razmovski, V., & Roufogalis, B. D. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960102.x · Cited by 123
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production
Hein, G. J., Baker, C., Hsieh, J., Farr, S., & Adeli, K. (2012) · Diabetes · doi:10.2337/db12-0202 · Cited by 121
Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles
Ståhlman, M., Fagerberg, B., Adiels, M., Ekroos, K., Chapman, J., Kontush, A., & Borén, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.07.009 · Cited by 125
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0529-3 · Cited by 126
Helicobacter pyloriinfection and diabetes: Is it a myth or fact
He, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4607 · Cited by 128
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 116
Evaluation of loganin, iridoid glycoside from Corni Fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice
Yamabe, N., Noh, J. S., Park, C. H., Kang, K. S., Shibahara, N., Tanaka, T., & Yokozawa, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.044 · Cited by 111
Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
Graham, I. M., Cooney, M. T., Bradley, D., Dudina, A. L., & Reiner, Ž. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0313-7 · Cited by 113
Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders
Meneses, M. J., Silvestre, R. D., Sousa‐Lima, I., & Macedo, M. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164049 · Cited by 118
Postprandial inflammation and endothelial dysfuction
Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350466 · Cited by 108
A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance
Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 110
Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation
Barrett, T. J., Distel, E., Murphy, A. J., Hu, J., Garshick, M. S., Ogando, Y., Liu, J. J., Vaisar, T., Heinecke, J. W., Berger, J. S., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039476 · Cited by 102

Authors: Taskinen, M.-R.
Affiliations: University of Helsinki (FI)
Corresponding author: Taskinen, M.-R.
ORCID: Taskinen, M.-R.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2003-06-01
Volume: 46
Issue: 6
Pages: 733-749
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-003-1111-y
OpenAlex: W2020659754
Cited by: 888
References: 183
Citations by year: 2026: 27 · 2025: 37 · 2024: 32 · 2023: 36 · 2022: 48 · 2021: 41 · 2020: 39 · 2019: 27 · 2018: 32 · 2017: 28 · 2016: 29 · 2015: 47 · 2014: 41 · 2013: 46 · 2012: 42
FWCI: 6.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Funders: Helsingin ja Uudenmaan Sairaanhoitopiiri
Academy of Finland
Diabetesliitto
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: diabetic dyslipidemia, type 2 diabetes, small dense LDL, triglyceride-rich lipoproteins, VLDL assembly, hepatic lipid metabolism, insulin signaling, PI3-kinase, SREBP-1c, de novo lipogenesis, apolipoprotein B-100, peroxisome proliferator-activated receptors, SREBP1, liver X receptor
MeSH terms: Diabetes Mellitus, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Lipoproteins, Lipoproteins, VLDL, Diabetes Complications, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diabetic dyslipidaemia: from basic research to clinical practice*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks